Detalhe da pesquisa
1.
It Takes 2 to Tango. Setting Out the Conditions in Which Performance-Based Risk-Sharing Arrangements Work for Both Parties.
Value Health
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38615938
2.
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom.
Value Health
; 26(3): 328-335, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738786
3.
Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology.
Value Health
; 2022 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35977878
4.
Considering Severity in Health Technology Assessment: Can We Do Better?
Value Health
; 25(8): 1399-1403, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35393254
5.
Estimating health system opportunity costs: the role of non-linearities and inefficiency.
Cost Eff Resour Alloc
; 20(1): 56, 2022 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309687
6.
Should We Pay for Scientific Knowledge Spillovers? The Underappreciated Value of "Failed" R&D Efforts.
Int J Technol Assess Health Care
; 38(1): e31, 2022 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35297363
7.
How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?
Value Health
; 24(5): 625-631, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33933230
8.
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations.
Value Health
; 24(11): 1628-1633, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711363
9.
Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?
Cost Eff Resour Alloc
; 19(1): 13, 2021 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33648523
10.
Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop.
BMC Health Serv Res
; 21(1): 412, 2021 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33941174
11.
Establishing a reasonable price for an orphan drug.
Cost Eff Resour Alloc
; 18: 31, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32908456
12.
Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?
Value Health
; 22(6): 677-683, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31198185
13.
Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
Value Health
; 21(2): 140-145, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29477391
14.
Paying for Cures: Perspectives on Solutions to the "Affordability Issue".
Value Health
; 21(3): 276-279, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29566833
15.
Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].
Value Health
; 21(2): 146-154, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29477392
16.
A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
Value Health
; 21(2): 161-165, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29477394
17.
Real Option Value: Should We Opt in or out?
Value Health
; 2022 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36209043
18.
Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis.
Value Health
; 20(2): 213-216, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28237197
19.
ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA.
Int J Technol Assess Health Care
; 33(2): 315-322, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28554337
20.
Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.
Health Econ
; 24(2): 238-52, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24293058